Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection
RSV感染临床前模型中妊娠对疫苗诱导免疫和保护的评价
基本信息
- 批准号:10470252
- 负责人:
- 金额:$ 76.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-24 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcuteAddressAdultAffectAnimal ModelAnimalsAntibody ResponseBlood group antigen fChildChildhoodClinicalClinical ResearchClinical TrialsDiseaseEnvironmentEtiologyEvaluationEvolutionExposure toFailureFemaleFormalinGoalsHumanImmuneImmune responseImmunityImmunizationInfantInfectionInfiltrationInnate Immune SystemKineticsLower Respiratory Tract InfectionLungLymphocyteMacacaMaternal antibodyMaternally-Acquired ImmunityMediatingMemoryMemory B-LymphocyteModelingMolecular ConformationMonoclonal AntibodiesMorbidity - disease rateMothersMucous body substanceNaturePassive ImmunityPassive Transfer of ImmunityPhenotypePopulationPre-Clinical ModelPredispositionPregnancyPreventionPrimatesProductionPublic HealthPulmonary PathologyReproducibilityRespiratory DiseaseRespiratory Signs and SymptomsRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory syncytial virusRespiratory syncytial virus RSV F proteinsRodent ModelRouteSecond Pregnancy TrimesterSerologySpecificityT-LymphocyteTestingTh2 CellsTherapeuticThird Pregnancy TrimesterVaccinatedVaccinationVaccinesVirusVirus-like particlebaseclinically relevantdesignefficacy testingexperiencehuman diseaseimmunopathologyimprovedinfant infectionmaternal vaccinationmature animalmortalityneonateneutralizing antibodyneutrophilnonhuman primatenovelnovel vaccinesoffspringperinatal periodpostnatal periodpregnantpreventprotective efficacyrecombinant virusresponseseropositivetransmission processvaccination strategyvaccine candidatevaccine developmentvaccine efficacyvaccine responsevaccine strategyvaccine-induced immunity
项目摘要
RSV is the leading cause of acute lower respiratory tract infections in children, causing an estimated 33 million
new infections each year. Despite this significant global burden, there is no RSV vaccine and there are currently
limited therapeutic options for severe RSV infection. Vaccine efforts have been hindered by 1) failure of early
vaccine attempts using formalin-inactivated RSV (FI-RSV) which led to the occurrence of enhanced respiratory
disease (ERD) in some infants and 2) deficiencies of rodent models that do not to recapitulate critical aspects of
human infant RSV infection. Studies have shown that vaccination with FI-RSV and subsequent RSV challenge
skews Th2-cell mediated responses towards immunopathology, while prior exposure to live virus properly primes
the adaptive and innate immune systems without ERD. Consequently, the potential for subunit and inactivated
RSV vaccines to cause ERD remains a particular concern for RSV naïve pediatric population. In this proposal,
we offer a novel immunization strategy in a highly relevant, pre-clinical model of RSV that addresses these
barriers to vaccine development. We propose to test novel maternal immunization strategies for eliciting
protective maternal immunity and test the protective efficacy of passive transfer of neutralizing antibodies. We
hypothesize that this approach will provide protective passive immunity in infants during perinatal period of
greatest RSV susceptibility. We propose to test this approach in a non-human primate model of RSV infection
using recombinant virus-like particle (VLP) vaccines expressing F antigen in appropriate conformation. In
addition, we will use this immunization strategy to improve understanding of critical aspects of maternal
immunization including 1) the effects of pregnancy on vaccine-induced immunity 2) the kinetics of maternal
transfer of neutralizing antibodies responses and 3) the efficacy of maternal immunization and protection in a
clinically relevant infant primate model. In addition, we will define innate and adaptive immune correlates of
protection in RSV infection in adult macaques, information that will be critical to the understanding of deficiencies
in the infant lung environment. We expect these studies will have a catalytic effect on the RSV field by
establishing a pre-clinical model of infection for design and testing maternal immunization strategies as well as in
a highly relevant, pre-clinical model that most closely mimics human disease.
RSV 是儿童急性下呼吸道感染的主要原因,估计导致 3300 万人感染
每年都有新的感染。尽管全球负担巨大,但目前还没有 RSV 疫苗
严重 RSV 感染的治疗选择有限。疫苗工作因以下原因受到阻碍:1)早期失败
尝试使用福尔马林灭活的 RSV (FI-RSV) 进行疫苗接种,导致出现增强的呼吸道症状
一些婴儿的疾病(ERD)和2)啮齿动物模型的缺陷,不能概括关键方面
人类婴儿 RSV 感染。研究表明,接种 FI-RSV 疫苗和随后的 RSV 攻击
使 Th2 细胞介导的反应偏向免疫病理学,而之前接触活病毒会正确启动
没有 ERD 的适应性和先天免疫系统。因此,亚基和失活的潜力
RSV 疫苗导致 ERD 仍然是未接触过 RSV 的儿科人群特别关注的问题。在这个提案中,
我们在高度相关的 RSV 临床前模型中提供了一种新颖的免疫策略,可以解决这些问题
疫苗开发的障碍。我们建议测试新的孕产妇免疫策略以引发
保护母体免疫力并测试中和抗体被动转移的保护功效。我们
假设这种方法将为婴儿在围产期提供保护性被动免疫
RSV 敏感性最高。我们建议在非人类灵长类动物 RSV 感染模型中测试这种方法
使用以适当构象表达 F 抗原的重组病毒样颗粒 (VLP) 疫苗。在
此外,我们将利用这一免疫策略来增进对孕产妇关键方面的了解
免疫包括 1) 妊娠对疫苗诱导免疫的影响 2) 母体的动力学
中和抗体反应的转移以及 3) 母体免疫和保护的功效
临床相关的婴儿灵长类动物模型。此外,我们将定义先天性和适应性免疫相关性
成年猕猴 RSV 感染的保护,对于理解缺陷至关重要的信息
在婴儿肺部环境中。我们预计这些研究将对 RSV 领域产生催化作用
建立临床前感染模型,用于设计和测试孕产妇免疫策略以及
高度相关的临床前模型,最接近地模拟人类疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karen A Norris其他文献
Karen A Norris的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karen A Norris', 18)}}的其他基金
Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection
RSV感染临床前模型中妊娠对疫苗诱导免疫和保护的评价
- 批准号:
10269922 - 财政年份:2020
- 资助金额:
$ 76.89万 - 项目类别:
Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection
RSV感染临床前模型中妊娠对疫苗诱导免疫和保护的评价
- 批准号:
10119736 - 财政年份:2020
- 资助金额:
$ 76.89万 - 项目类别:
Prevention and Treatment of Pneumocystis Pneumonia
肺孢子虫肺炎的防治
- 批准号:
10605177 - 财政年份:2020
- 资助金额:
$ 76.89万 - 项目类别:
Prevention and Treatment of Pneumocystis Pneumonia
肺孢子虫肺炎的防治
- 批准号:
10382422 - 财政年份:2020
- 资助金额:
$ 76.89万 - 项目类别:
Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection
RSV感染临床前模型中妊娠对疫苗诱导免疫和保护的评价
- 批准号:
10685614 - 财政年份:2020
- 资助金额:
$ 76.89万 - 项目类别:
Immunopathogenesis of HIV-associated pulmonary hypertension
HIV相关肺动脉高压的免疫发病机制
- 批准号:
9370162 - 财政年份:2016
- 资助金额:
$ 76.89万 - 项目类别:
Immune dysfunction and pulmonary hypertension in primate model of HIV infection
HIV感染灵长类动物模型中的免疫功能障碍和肺动脉高压
- 批准号:
9404231 - 财政年份:2014
- 资助金额:
$ 76.89万 - 项目类别:
Serologic memory and prevention of Pneumocystis-related COPD in AIDS macaque mode
艾滋病猕猴模型肺孢子虫相关慢性阻塞性肺病的血清学记忆和预防
- 批准号:
8298380 - 财政年份:2011
- 资助金额:
$ 76.89万 - 项目类别:
T. cruzi immune evasion factors and vaccine design
克氏锥虫免疫逃避因素和疫苗设计
- 批准号:
7448591 - 财政年份:2007
- 资助金额:
$ 76.89万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 76.89万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 76.89万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 76.89万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 76.89万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 76.89万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 76.89万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 76.89万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 76.89万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 76.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 76.89万 - 项目类别:
Standard Grant